Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
The Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia meeting, held in New York, included topics covering new therapeutic developments in the field of PDE inhibitors for the treatment of cognitive dysfunction. This conference report highlights selected presentations on inhibitors of PDE1, PDE4, PDE5, PDE8, PDE9 and PDE10 for schizophrenia-related cognitive disorders. Investigational drugs discussed include PF-2545920 (Pfizer Inc).